198 related articles for article (PubMed ID: 35907883)
1. Modulation of hepatic stellate cells by Mutaflor
Hany NM; Eissa S; Basyouni M; Hasanin AH; Aboul-Ela YM; Elmagd NMA; Montasser IF; Ali MA; Skipp PJ; Matboli M
J Transl Med; 2022 Jul; 20(1):342. PubMed ID: 35907883
[TBL] [Abstract][Full Text] [Related]
2. Probiotic-prebiotic-synbiotic modulation of (YAP1, LATS1 and NF2 mRNAs/miR-1205/lncRNA SRD5A3-AS1) panel in NASH animal model.
Gadallah SH; Eissa S; Ghanem HM; Ahmed EK; Hasanin AH; El Mahdy MM; Matboli M
Biomed Pharmacother; 2021 Aug; 140():111781. PubMed ID: 34090052
[TBL] [Abstract][Full Text] [Related]
3. mRNA-miRNA-lncRNA Regulatory Network in Nonalcoholic Fatty Liver Disease.
Matboli M; Gadallah SH; Rashed WM; Hasanin AH; Essawy N; Ghanem HM; Eissa S
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34202571
[TBL] [Abstract][Full Text] [Related]
4. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells.
Chong LW; Hsu YC; Lee TF; Lin Y; Chiu YT; Yang KC; Wu JC; Huang YT
BMC Gastroenterol; 2015 Feb; 15():22. PubMed ID: 25886887
[TBL] [Abstract][Full Text] [Related]
5. Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity.
Larsen FT; Hansen D; Terkelsen MK; Bendixen SM; Avolio F; Wernberg CW; Lauridsen MM; Grønkjaer LL; Jacobsen BG; Klinggaard EG; Mandrup S; Di Caterino T; Siersbæk MS; Indira Chandran V; Graversen JH; Krag A; Grøntved L; Ravnskjaer K
JHEP Rep; 2023 Feb; 5(2):100615. PubMed ID: 36687468
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the role of kefir in management of non-alcoholic steatohepatitis rat model via modulation of NASH linked mRNA-miRNA panel.
Salah N; Eissa S; Mansour A; El Magd NMA; Hasanin AH; El Mahdy MM; Hassan MK; Matboli M
Sci Rep; 2023 Jan; 13(1):236. PubMed ID: 36604518
[TBL] [Abstract][Full Text] [Related]
7. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV
PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606
[TBL] [Abstract][Full Text] [Related]
8. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
[TBL] [Abstract][Full Text] [Related]
9. Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis: analysis of isolated hepatic stellate cells.
Kim M; Yang SG; Kim JM; Lee JW; Kim YS; Lee JI
Int J Mol Med; 2012 Sep; 30(3):473-9. PubMed ID: 22710359
[TBL] [Abstract][Full Text] [Related]
10. Novel oral SPT inhibitor CH5169356 inhibits hepatic stellate cell activation and ameliorates hepatic fibrosis in mouse models of non-alcoholic steatohepatitis (NASH).
Hada N; Katsume A; Kenichi K; Endo C; Horiba N; Sudoh M
Pharmacol Res Perspect; 2023 Jun; 11(3):e01094. PubMed ID: 37204099
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis.
Lakner AM; Steuerwald NM; Walling TL; Ghosh S; Li T; McKillop IH; Russo MW; Bonkovsky HL; Schrum LW
Hepatology; 2012 Jul; 56(1):300-10. PubMed ID: 22278637
[TBL] [Abstract][Full Text] [Related]
12. Aerobic exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis.
Linden MA; Sheldon RD; Meers GM; Ortinau LC; Morris EM; Booth FW; Kanaley JA; Vieira-Potter VJ; Sowers JR; Ibdah JA; Thyfault JP; Laughlin MH; Rector RS
J Physiol; 2016 Sep; 594(18):5271-84. PubMed ID: 27104887
[TBL] [Abstract][Full Text] [Related]
13. Altered expression of MALAT1 lncRNA in nonalcoholic steatohepatitis fibrosis regulates CXCL5 in hepatic stellate cells.
Leti F; Legendre C; Still CD; Chu X; Petrick A; Gerhard GS; DiStefano JK
Transl Res; 2017 Dec; 190():25-39.e21. PubMed ID: 28993096
[TBL] [Abstract][Full Text] [Related]
14. Osteopontin is a proximal effector of leptin-mediated non-alcoholic steatohepatitis (NASH) fibrosis.
Coombes JD; Choi SS; Swiderska-Syn M; Manka P; Reid DT; Palma E; Briones-Orta MA; Xie G; Younis R; Kitamura N; Della Peruta M; Bitencourt S; Dollé L; Oo YH; Mi Z; Kuo PC; Williams R; Chokshi S; Canbay A; Claridge LC; Eksteen B; Diehl AM; Syn WK
Biochim Biophys Acta; 2016 Jan; 1862(1):135-44. PubMed ID: 26529285
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease.
Romualdo GR; Da Silva TC; de Albuquerque Landi MF; Morais JÁ; Barbisan LF; Vinken M; Oliveira CP; Cogliati B
Environ Toxicol; 2021 Feb; 36(2):168-176. PubMed ID: 32918399
[TBL] [Abstract][Full Text] [Related]
16. H19/miR-148a/USP4 axis facilitates liver fibrosis by enhancing TGF-β signaling in both hepatic stellate cells and hepatocytes.
Zhu J; Luo Z; Pan Y; Zheng W; Li W; Zhang Z; Xiong P; Xu D; Du M; Wang B; Yu J; Zhang J; Liu J
J Cell Physiol; 2019 Jun; 234(6):9698-9710. PubMed ID: 30362572
[TBL] [Abstract][Full Text] [Related]
17. Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic Treatment of Non-Alcoholic Fatty Liver Disease.
Kimura T; Singh S; Tanaka N; Umemura T
Front Endocrinol (Lausanne); 2021; 12():773432. PubMed ID: 34938271
[TBL] [Abstract][Full Text] [Related]
18. SIRT6 Protects Against Liver Fibrosis by Deacetylation and Suppression of SMAD3 in Hepatic Stellate Cells.
Zhong X; Huang M; Kim HG; Zhang Y; Chowdhury K; Cai W; Saxena R; Schwabe RF; Liangpunsakul S; Dong XC
Cell Mol Gastroenterol Hepatol; 2020; 10(2):341-364. PubMed ID: 32305562
[TBL] [Abstract][Full Text] [Related]
19. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.
Ceccarelli S; Panera N; Mina M; Gnani D; De Stefanis C; Crudele A; Rychlicki C; Petrini S; Bruscalupi G; Agostinelli L; Stronati L; Cucchiara S; Musso G; Furlanello C; Svegliati-Baroni G; Nobili V; Alisi A
Oncotarget; 2015 Dec; 6(39):41434-52. PubMed ID: 26573228
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of miR-188-5p alleviates hepatic fibrosis by significantly reducing the activation and proliferation of HSCs through PTEN/PI3K/AKT pathway.
Riaz F; Chen Q; Lu K; Osoro EK; Wu L; Feng L; Zhao R; Yang L; Zhou Y; He Y; Zhu L; Du X; Sadiq M; Yang X; Li D
J Cell Mol Med; 2021 Apr; 25(8):4073-4087. PubMed ID: 33689215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
